^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
JS203
i
Other names: JS203
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Shanghai Junshi Biosci
Drug class:
CD20 inhibitor, CD3 agonist
Related drugs:
2d
Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P1, N=104, Active, not recruiting, Shanghai Junshi Bioscience Co., Ltd. | Recruiting --> Active, not recruiting | N=219 --> 104 | Trial primary completion date: Dec 2025 --> Dec 2026
Enrollment closed • Enrollment change • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
JS203
4ms
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P2, N=180, Recruiting, Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
carboplatin • gemcitabine • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • vincristine • prednisone • JS203
4ms
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P2, N=180, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.
New P2 trial
|
carboplatin • gemcitabine • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • vincristine • prednisone • JS203
6ms
Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P1, N=219, Recruiting, Shanghai Junshi Bioscience Co., Ltd. | Trial completion date: Feb 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
JS203
over2years
Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P1, N=219, Recruiting, Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
CD20 (Membrane Spanning 4-Domains A1) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
CD20 expression
|
JS203
3years
Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P1, N=219, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.
New P1 trial
|
CD20 (Membrane Spanning 4-Domains A1) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
CD20 expression
|
JS203
Share via
